Prognostic Predictive Characteristics in Patients With Fibrosing Interstitial Lung Disease: A Retrospective Cohort Study

被引:12
作者
Wang, Yuanying [1 ]
Guo, Ziyun [1 ]
Ma, Ruimin [1 ]
Wang, Jingwei [1 ]
Wu, Na [1 ,2 ]
Fan, Yali [1 ]
Ye, Qiao [1 ,2 ]
机构
[1] Capital Med Univ, Beijing Chaoyang Hosp, Beijing Inst Resp Med, Clin Ctr Interstitial Lung Dis, Beijing, Peoples R China
[2] Capital Med Univ, Beijing Chaoyang Hosp, Dept Occupat Med & Toxicol, Beijing, Peoples R China
基金
中国国家自然科学基金;
关键词
progressive fibrosing interstitial lung disease; prognosis; lung function test; blood count values; anti-fibrotic treatment; IDIOPATHIC PULMONARY-FIBROSIS; PIRFENIDONE; DIAGNOSIS;
D O I
10.3389/fphar.2022.924754
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Limited data are available regarding the entire spectrum of interstitial lung disease with a progressive fibrosing feature. We investigated the prevalence and prognostic predictive characteristics in patients with PF-ILD.Methods: This retrospective cohort study included patients with fibrosing ILD who were investigated between 1 January 2015 and 30 April 2021. We recorded clinical features and outcomes to identify the possible risk factors for fibrosing progression as well as mortality.Results: Of the 579 patients with fibrosing ILD, 227 (39.21%) met the criteria for progression. Clubbing of fingers [odds ratio (OR) 1.52, 95% confidence interval (CI) 1.03 to 2.24, p = 0.035] and a high-resolution computed tomography (HRCT)-documented usual interstitial pneumonia (UIP)-like fibrotic pattern (OR 1.95, 95% CI 1.33 to 2.86, p = 0.001) were risk factors for fibrosis progression. The mortality was worse in patients with PF with hypoxemia [hazard ratio (HR) 2.08, 95% CI 1.31 to 3.32, p = 0.002], in those with baseline diffusion capacity of the lung for carbon monoxide (DLCO) % predicted <50% (HR 2.25, 95% CI 1.45 to 3.50, p < 0.001), or in those with UIP-like fibrotic pattern (HR 1.68, 95% CI 1.04 to 2.71, p < 0.001).Conclusion: Clubbing of fingers and an HRCT-documented UIP-like fibrotic pattern were more likely to be associated with progressive fibrosing with varied prevalence based on the specific diagnosis. Among patients with progressive fibrosing, those with hypoxemia, lower baseline DLCO% predicted, or UIP-like fibrotic pattern showed poor mortality.
引用
收藏
页数:11
相关论文
共 49 条
[1]   Risk factors for acute exacerbation following bronchoalveolar lavage in patients with suspected idiopathic pulmonary fibrosis: A retrospective cohort study [J].
Abe, Mitsuhiro ;
Tsushima, Kenji ;
Ishii, Daisuke ;
Shikano, Kohei ;
Yoshioka, Keiichiro ;
Sakayori, Masashi ;
Suzuki, Masaki ;
Hirasawa, Yasutaka ;
Ishiwata, Tsukasa ;
Kawasaki, Takeshi ;
Ikari, Jun ;
Terada, Jiro ;
Tatsumi, Koichiro .
ADVANCES IN RESPIRATORY MEDICINE, 2021, 89 (02) :101-109
[2]   Phenotypic Clusters Predict Outcomes in a Longitudinal Interstitial Lung Disease Cohort [J].
Adegunsoye, Ayodeji ;
Oldham, Justin M. ;
Chung, Jonathan H. ;
Montner, Steven M. ;
Lee, Cathryn ;
Witt, Leah J. ;
Stahlbaum, Danielle ;
Bermea, Rene S. ;
Chen, Lena W. ;
Hsu, Scully ;
Husain, Aliya N. ;
Noth, Imre ;
Vij, Rekha ;
Strek, Mary E. ;
Churpek, Matthew .
CHEST, 2018, 153 (02) :349-360
[3]   Use of peripheral neutrophil to lymphocyte ratio and peripheral monocyte levels to predict survival in fibrotic hypersensitivity pneumonitis (fHP): a multicentre retrospective cohort study [J].
Barratt, Shaney L. ;
Creamer, Andrew W. ;
Adamali, Huzaifa, I ;
Duckworth, Anna ;
Fallon, Janet ;
Fidan, Silan ;
Nancarrow, Tom ;
Wollerton, Rebecca ;
Steward, Matthew ;
Gooptu, Bibek ;
Gibbons, Michael ;
Woodhead, Felix Alexander ;
Scotton, Chris .
BMJ OPEN RESPIRATORY RESEARCH, 2021, 8 (01)
[4]   Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial [J].
Behr, Juergen ;
Prasse, Antje ;
Kreuter, Michael ;
Johow, Johannes ;
Rabe, Klaus F. ;
Bonella, Francesco ;
Bonnet, Reiner ;
Grohe, Christian ;
Held, Matthias ;
Wilkens, Heinrike ;
Hammerl, Peter ;
Koschel, Dirk ;
Blaas, Stefan ;
Wirtz, Hubert ;
Ficker, Joachim H. ;
Neumeister, Wolfgang ;
Schoenfeld, Nicolas ;
Claussen, Martin ;
Kneidinger, Nikolaus ;
Frankenberger, Marion ;
Hummler, Simone ;
Kahn, Nicolas ;
Tello, Silke ;
Freise, Julia ;
Welte, Tobias ;
Neuser, Petra ;
Guenther, Andreas .
LANCET RESPIRATORY MEDICINE, 2021, 9 (05) :476-486
[5]   Predictors of Mortality in Progressive Fibrosing Interstitial Lung Diseases [J].
Chen, Xianqiu ;
Guo, Jian ;
Yu, Dong ;
Jie, Bing ;
Zhou, Ying .
FRONTIERS IN PHARMACOLOGY, 2021, 12
[6]   Hypersensitivity pneumonitis: new concepts and classifications [J].
Churg, Andrew .
MODERN PATHOLOGY, 2022, 35 (SUPPL 1) :15-27
[7]   An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP) [J].
Costabel, Ulrich ;
Albera, Carlo ;
Lancaster, Lisa H. ;
Lin, Chin-Yu ;
Hormel, Philip ;
Hulter, Henry N. ;
Noble, Paul W. .
RESPIRATION, 2017, 94 (05) :408-415
[8]   Fibrosing interstitial lung diseases: knowns and unknowns [J].
Cottin, Vincent ;
Wollin, Lutz ;
Fischer, Aryeh ;
Quaresma, Manuel ;
Stowasser, Susanne ;
Harari, Sergio .
EUROPEAN RESPIRATORY REVIEW, 2019, 28 (151)
[9]   Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases [J].
Cottin, Vincent ;
Hirani, Nikhil A. ;
Hotchkin, David L. ;
Nambiar, Anoop M. ;
Ogura, Takashi ;
Otaola, Maria ;
Skowasch, Dirk ;
Park, Jong Sun ;
Poonyagariyagorn, Hataya K. ;
Wuyts, Wim ;
Wells, Athol U. .
EUROPEAN RESPIRATORY REVIEW, 2018, 27 (150)
[10]   Nintedanib in Progressive Fibrosing Interstitial Lung Diseases [J].
Flaherty, K. R. ;
Wells, A. U. ;
Cottin, V ;
Devaraj, A. ;
Walsh, S. L. F. ;
Inoue, Y. ;
Richeldi, L. ;
Kolb, M. ;
Tetzlaff, K. ;
Stowasser, S. ;
Coeck, C. ;
Clerisme-Beaty, E. ;
Rosenstock, B. ;
Quaresma, M. ;
Haeufel, T. ;
Goeldner, R-G ;
Schlenker-Herceg, R. ;
Brown, K. K. .
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (18) :1718-1727